Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ESMO
Filter by Topic
ESMO 2010 Conference
ESMO 2011 Conference
ESMO 2012 Conference
ESMO 2013 Conference
ESMO 2014 - Gastrointestinal and Head & Neck Cancer
ESMO 2014 - Immuno-Oncology
ESMO 2014 - Prostate Cancer
ESMO 2014 Highlights
ESMO 2016
ESMO 2017 Highlights
ESMO 2018
ESMO 2019
Adding Docetaxel to ADT Significantly Improves Survival versus ADT Alone in Patients with High-Volume Metastatic Prostate Cancer
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read Article
Early PSA Response as a Prognostic Factor in Metastatic Prostate Cancer
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read Article
Emerging Agents for Metastatic Prostate Cancer: Galeterone, Selinexor, and ARN-509
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read Article
Sequencing Abiraterone Acetate, Cabazitaxel, and Enzalutamide in Post-Docetaxel mCRPC: Exploiting Efficacy and Avoiding Cross-Resistance
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read Article
Second-Generation ALK Inhibitor Regresses Brain Metastases in Patients with Lung Cancer
By
Phoebe Starr
ESMO 2013 Conference
,
ESMO
October 2013, Vol 4, No 8
Amsterdam, The Netherlands—The novel ALK/EGFR inhibitor known as AP26113 achieved good responses in reducing brain metastases in patients with crizotinib (Xalkori)-resistant and crizotinib-nave non–small-cell lung cancer (NSCLC), as well as radiographic regression of central nervous system (CNS) metastases.
Read Article
Kadcyla Prolongs Survival in Advanced HER2-Positive Breast Cancer
By
Phoebe Starr
ESMO 2013 Conference
,
ESMO
October 2013, Vol 4, No 8
Amsterdam, The Netherlands—The antibody-conjugate ado-trastuzumab emtansine (Kadcyla), also known as T-DM1, prolonged progression-free survival (PFS) in advanced HER2-positive breast cancer in a heavily pretreated population, according to the final results of the phase 3 clinical trial TH3RESA.
Read Article
The State of Cancer Globally in 2013
By
Audrey Andrews
ESMO 2013 Conference
,
ESMO
October 2013, Vol 4, No 8
Amsterdam, The Netherlands—Although much progress has been made in cancer care over the past couple of decades, a report presented at the 2013 European Cancer Congress emphasizes that on a global scale, the impact is far from equitable.
Read Article
MPDL3280A: Responses Better in Smokers than in Nonsmokers in Advanced Lung Cancer
By
Phoebe Starr
ESMO 2013 Conference
,
ESMO
October 2013, Vol 4, No 8
Amsterdam, The Netherlands—For the first time, a therapy for non–small-cell lung cancer (NSCLC) has achieved responses in smokers better than in nonsmokers. The antibody MPDL3280A also achieved good responses in squamous and adenoma histologic types of NSCLC.
Read Article
Cost-Effectiveness Comparison of First-Line Therapies for Advanced Non–Small-Cell Lung Cancer
By
Caroline Helwick
ESMO 2012 Conference
,
ESMO
November 2012, Vol 3, No 8
Vienna, Austria—Costs associated with first-line pemetrexed/cisplatin are significantly lower than those of carboplatin/paclitaxel/bevacizumab for the treatment of advanced non–small-cell lung cancer (NSCLC), according to an analysis presented at the 2012 European Society for Medical Oncology Congress.
Read Article
Platinum-Resistant Ovarian Cancer: Bevacizumab Improves Survival When Added to Chemotherapy
By
Phoebe Starr
ESMO 2012 Conference
,
ESMO
November 2012, Vol 3, No 8
Vienna, Austria—Adding bevacizumab (Avastin) to chemotherapy improves outcomes in patients with platinum-resistant recurrent ovarian cancer, according to results of the phase 3 clinical trial AURELIA, which was presented at the 2012 European Society for Medical Oncology Congress.
Read Article
Page 6 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma